Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News August 21st 2009

August 21st 2009

Insulin Resistance and Oxidative Stress in Children Born Small and Large for Gestational Age
Increased IR and oxidative stress are already present in prepubertal normal-weight SGA and LGA children with a continuous alteration in relation to obesity, suggesting that BW and adiposity represent 2 independent risk factors for degenerative diseases (Pediatrics)

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study
Among older patients with diabetes, pioglitazone is associated with a significantly lower risk of heart failure and death than is rosiglitazone. Given that rosiglitazone lacks a distinct clinical advantage over pioglitazone, continued use of rosiglitazone may not be justified (BMJ)

Rosiglitazone or pioglitazone in type 2 diabetes?
Longer term safety data are needed before a change in practice is warranted (Editorial BMJ, UK]

Insulin-treated diabetes in Australia 2000-2007
This report shows that the incidence of Type 1 and other insulin-treated diabetes in Australia is increasing and people with insulin-treated diabetes have significantly higher death rates than other Australians (AIHW, Australia)

Glycemic Control in Youth with Diabetes: The SEARCH for Diabetes in Youth Study
The high percentage of US youth with HbA1c levels above the target value and with poor glycemic control indicates an urgent need for effective treatment strategies to improve metabolic status in youth with diabetes (Journal of Pediatrics)

A cohort study of the risk of cancer associated with type 2 diabetes
Significantly increased risks were observed for pancreatic, liver and colon cancer (British Journal of Cancer)

Takeda Reacquires Canadian Rights to Leading Diabetes Drug from Eli Lilly Canada
Takeda Canada, Inc. announced that it has reacquired the Canadian commercial rights to ACTOS(R) (pioglitazone HCl), an oral treatment for type 2 diabetes, from Eli Lilly Canada Inc. (BioSpace)

Categories: News Pre-2012

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

AstraZenecaNapp DiabetesBoehringer IngelheimNovo Nordisk

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)About Ascensia Diabetes CareAbbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership